Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic,Nicole Blijlevens,Yok-Lam Kwong,Uzma Zaidi,Fausto Castagnetti,Paolo Gallipoli,Maria Cristina Miggiano,Peter E. Westerweel,Melissa Chen, Carmen Garcia Hernandez,William J. Kell,Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth,Germano Ferreira,Jeroen J. W. M. Janssen

BLOOD（2023）

引用 0|浏览13

暂无评分

摘要

Background: In patients (pts) with CML, the BCR::ABL1 T315I gatekeeper mutation confers treatment resistance to all approved ATP-competitive tyrosine kinase inhibitors (TKIs) except ponatinib and olverembatinib; thus pts harboring this mutation have limited treatment options.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要